{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T09:10:01Z","timestamp":1792919401583,"version":"4.5.0"},"reference-count":83,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.beem.2022.101713","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T09:13:38Z","timestamp":1665652418000},"page":"101713","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Temozolomide in aggressive pituitary tumours and pituitary carcinomas"],"prefix":"10.1016","volume":"36","author":[{"given":"Ann","family":"McCormack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beem.2022.101713_bib1","first-page":"621","article-title":"Long-term response of pituitary carcinoma to temozolomide. Report of two cases","volume":"105","author":"Fadul","year":"2006","journal-title":"J\u00a0Neurosurg"},{"issue":"2","key":"10.1016\/j.beem.2022.101713_bib2","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11154-020-09551-y","article-title":"Temozolomide therapy for aggressive pituitary tumours - current understanding and future perspectives","volume":"21","author":"Burman","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.beem.2022.101713_bib3","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-17-0796","article-title":"European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas","volume":"178","author":"Raverot","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1530\/EJE-17-0933","article-title":"Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016","volume":"178","author":"McCormack","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11060-015-1991-y","article-title":"Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas","volume":"126","author":"Losa","year":"2016","journal-title":"J\u00a0Neuro Oncol"},{"issue":"4","key":"10.1016\/j.beem.2022.101713_bib6","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1210\/jc.2014-4350","article-title":"Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide","volume":"100","author":"Bengtsson","year":"2015","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.beem.2022.101713_bib7","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1530\/EJE-16-0979","article-title":"Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas","volume":"176","author":"Lasolle","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib8","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgz211","article-title":"Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas-A German survey","volume":"105","author":"Elbelt","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.beem.2022.101713_bib9","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.beem.2022.101713_bib10","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1158\/1078-0432.CCR-08-1476","article-title":"O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors","volume":"15","author":"Kulke","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.beem.2022.101713_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lungcan.2014.08.007","article-title":"Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase","volume":"86","author":"Zauderer","year":"2014","journal-title":"Lung Cancer"},{"issue":"5","key":"10.1016\/j.beem.2022.101713_bib12","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1097\/CMR.0b013e3283649a97","article-title":"Efficacy and side effects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-analysis consisting of 1314 patients","volume":"23","author":"Teimouri","year":"2013","journal-title":"Melanoma Res"},{"issue":"4","key":"10.1016\/j.beem.2022.101713_bib13","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1158\/0008-5472.CAN-16-2983","article-title":"Temozolomide in the era of precision medicine","volume":"77","author":"Thomas","year":"2017","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.beem.2022.101713_bib14","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.beem.2022.101713_bib15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1158\/1078-0432.CCR-16-1040","article-title":"PARP inhibitor activity correlates with SLFN11 expression and demonstrates synergy with temozolomide in small cell lung cancer","volume":"23","author":"Lok","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.beem.2022.101713_bib16","doi-asserted-by":"crossref","first-page":"E280","DOI":"10.1210\/jc.2010-0441","article-title":"Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression","volume":"95","author":"Bush","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2022.101713_bib17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11060-020-03579-5","article-title":"Stereotactic reirradiation with temozolomide in patients with recurrent aggressive pituitary tumors and pituitary carcinomas","volume":"149","author":"Minniti","year":"2020","journal-title":"J\u00a0Neuro Oncol"},{"issue":"12","key":"10.1016\/j.beem.2022.101713_bib18","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1200\/JCO.2009.26.5520","article-title":"Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study","volume":"28","author":"Perry","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"32","key":"10.1016\/j.beem.2022.101713_bib19","doi-asserted-by":"crossref","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","article-title":"Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial","volume":"31","author":"Gilbert","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beem.2022.101713_bib20","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.700007","article-title":"Clinical efficacy of temozolomide and its predictors in aggressive pituitary tumors and pituitary carcinomas: a systematic review and meta-analysis","volume":"12","author":"Luo","year":"2021","journal-title":"Front Neurol"},{"issue":"8","key":"10.1016\/j.beem.2022.101713_bib21","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1210\/jc.2014-1183","article-title":"Multiple cerebral hemorrhagic foci from metastases during temozolomide treatment in a patient with corticotroph pituitary carcinoma","volume":"99","author":"Mendola","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2022.101713_bib22","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1007\/s11102-015-0694-x","article-title":"Temozolomide for aggressive ACTH pituitary tumors: failure of a second course of treatment","volume":"19","author":"Campdera","year":"2016","journal-title":"Pituitary"},{"issue":"12","key":"10.1016\/j.beem.2022.101713_bib23","doi-asserted-by":"crossref","first-page":"e476","DOI":"10.1097\/MD.0000000000000476","article-title":"Severe cholestatic hepatitis due to temozolomide: an adverse drug effect to keep in mind. Case report and review of literature","volume":"94","author":"Grieco","year":"2015","journal-title":"Medicine (Baltim)"},{"issue":"4","key":"10.1016\/j.beem.2022.101713_bib24","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11102-020-01040-4","article-title":"Long-course temozolomide in aggressive pituitary adenoma: real-life experience in two tertiary care centers and review of the literature","volume":"23","author":"Lizzul","year":"2020","journal-title":"Pituitary"},{"key":"10.1016\/j.beem.2022.101713_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.774686","article-title":"Early initiation of temozolomide therapy may improve response in aggressive pituitary adenomas","volume":"12","author":"Das","year":"2021","journal-title":"Front Endocrinol"},{"issue":"10","key":"10.1016\/j.beem.2022.101713_bib26","doi-asserted-by":"crossref","first-page":"4592","DOI":"10.1210\/jc.2010-0644","article-title":"Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience","volume":"95","author":"Raverot","year":"2010","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2022.101713_bib27","doi-asserted-by":"crossref","first-page":"bvab065","DOI":"10.1210\/jendso\/bvab065","article-title":"Long-term use of temozolomide as safe and effective therapy for an aggressive corticotroph adenoma in a very old patient","volume":"5","author":"Decaroli","year":"2021","journal-title":"J\u00a0Endocr Soc"},{"key":"10.1016\/j.beem.2022.101713_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.wneu.2018.07.082","article-title":"Early recognition and initiation of temozolomide chemotherapy for refractory, invasive pituitary macroprolactinoma with long-term sustained remission","volume":"118","author":"Barkhoudarian","year":"2018","journal-title":"World Neurosurg"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib29","first-page":"188","article-title":"Temozolomide treatment of pituitary carcinomas and atypical adenomas: systematic review of case reports","volume":"3","author":"Ji","year":"2016","journal-title":"Neurooncol Pract"},{"issue":"4","key":"10.1016\/j.beem.2022.101713_bib30","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1530\/EJE-18-0795","article-title":"Treatment and long-term outcomes in pituitary carcinoma: a cohort study","volume":"181","author":"Santos-Pinheiro","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.beem.2022.101713_bib31","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.wneu.2018.11.011","article-title":"Long-term survival after transformation of an adrenocorticotropic hormone-secreting pituitary macroadenoma to a silent corticotroph pituitary carcinoma","volume":"122","author":"Rotman","year":"2019","journal-title":"World Neurosurg"},{"issue":"8","key":"10.1016\/j.beem.2022.101713_bib32","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1507\/endocrj.EJ18-0547","article-title":"Successful reduction of ACTH secretion in a case of intractable Cushing's disease with pituitary Crooke's cell adenoma by combined modality therapy including temozolomide","volume":"66","author":"Tanaka","year":"2019","journal-title":"Endocr J"},{"issue":"2","key":"10.1016\/j.beem.2022.101713_bib33","doi-asserted-by":"crossref","first-page":"bvab190","DOI":"10.1210\/jendso\/bvab190","article-title":"Temozolomide nonresponsiveness in aggressive prolactinomas and carcinomas: management and outcomes","volume":"6","author":"Das","year":"2022","journal-title":"J\u00a0Endocr Soc"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib34","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s11102-011-0363-7","article-title":"Temozolomide responsiveness in aggressive corticotroph tumours: a case report and review of the literature","volume":"15","author":"Annamalai","year":"2012","journal-title":"Pituitary"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib35","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1210\/jc.2012-2924","article-title":"DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors","volume":"98","author":"Hirohata","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2022.101713_bib36","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s42000-019-00145-1","article-title":"Is MGMT the best marker to predict response of temozolomide in aggressive pituitary tumors? Alternative markers and prospective treatment modalities","volume":"18","author":"Kontogeorgos","year":"2019","journal-title":"Hormones (Basel)"},{"issue":"6","key":"10.1016\/j.beem.2022.101713_bib37","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s11102-017-0829-3","article-title":"MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas","volume":"20","author":"Micko","year":"2017","journal-title":"Pituitary"},{"issue":"10","key":"10.1016\/j.beem.2022.101713_bib38","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1016\/j.beem.2022.101713_bib39","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/j.1365-2362.2011.02520.x","article-title":"Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status","volume":"41","author":"McCormack","year":"2011","journal-title":"Eur J Clin Invest"},{"issue":"7","key":"10.1016\/j.beem.2022.101713_bib40","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1158\/1078-0432.CCR-06-2149","article-title":"Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment","volume":"13","author":"Cahill","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.beem.2022.101713_bib41","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1210\/jc.2018-01347","article-title":"Marked response of a hypermutated ACTH-secreting pituitary carcinoma to ipilimumab and nivolumab","volume":"103","author":"Lin","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"7528","key":"10.1016\/j.beem.2022.101713_bib42","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.beem.2022.101713_bib43","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1210\/jc.2017-01401","article-title":"Corticotroph pituitary carcinoma in a patient with Lynch syndrome (LS) and pituitary tumors in a nationwide LS cohort","volume":"102","author":"Bengtsson","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.beem.2022.101713_bib44","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI59334","article-title":"Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients","volume":"122","author":"Agnihotri","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"10.1016\/j.beem.2022.101713_bib45","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2176\/nmc.ra.2018-0141","article-title":"Potential strategies overcoming the temozolomide resistance for glioblastoma","volume":"58","author":"Jiapaer","year":"2018","journal-title":"Neurol Med -Chir"},{"issue":"2","key":"10.1016\/j.beem.2022.101713_bib46","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s11102-021-01192-x","article-title":"Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex\u00a0vivo 3D spheroid assay","volume":"25","author":"Ishida","year":"2022","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.beem.2022.101713_bib47","doi-asserted-by":"crossref","first-page":"C7","DOI":"10.1530\/EJE-18-0250","article-title":"Aggressive pituitary tumours and carcinomas: two sides of the same coin?","volume":"178","author":"Trouillas","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.beem.2022.101713_bib48","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaa649","article-title":"Approach to the treatment of a patient with an aggressive pituitary tumor","volume":"105","author":"Lin","year":"2020","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2022.101713_bib49","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1177\/1078155212469243","article-title":"Impact of temozolomide on gonadal function in patients with primary malignant brain tumors","volume":"19","author":"Strowd","year":"2013","journal-title":"J\u00a0Oncol Pharm Pract"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib50","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1158\/1078-0432.CCR-07-1856","article-title":"In\u00a0vitro and in\u00a0vivo radiosensitization induced by the DNA methylating agent temozolomide","volume":"14","author":"Kil","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beem.2022.101713_bib51","article-title":"A\u00a0retrospective trail investigating temozolomide neoadjuvant chemotherapy combined with radiotherapy in low-grade pituitary tumors","volume":"2022","author":"Cui","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.beem.2022.101713_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.725014","article-title":"Treatment of aggressive pituitary adenomas: a case-based narrative review","volume":"12","author":"Cooper","year":"2021","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.beem.2022.101713_bib53","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bcp.12877","article-title":"Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment","volume":"81","author":"Derissen","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"1\u20132","key":"10.1016\/j.beem.2022.101713_bib54","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000500862","article-title":"Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor","volume":"110","author":"de Mestier","year":"2020","journal-title":"Neuroendocrinology"},{"issue":"41","key":"10.1016\/j.beem.2022.101713_bib55","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000012784","article-title":"Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms: a meta-analysis","volume":"97","author":"Lu","year":"2018","journal-title":"Medicine (Baltim)"},{"issue":"9","key":"10.1016\/j.beem.2022.101713_bib56","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1159\/000513218","article-title":"Temozolomide alone or combined with capecitabine for the treatment of metastatic neuroendocrine neoplasia: a \"Real-World\" data analysis","volume":"111","author":"Bongiovanni","year":"2021","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.beem.2022.101713_sref57","doi-asserted-by":"crossref","first-page":"E447","DOI":"10.1227\/NEU.0000000000000251","article-title":"High response rates and prolonged survival in patients with corticotroph pituitary tumors and refractory Cushing disease from capecitabine and temozolomide (CAPTEM): a case series","volume":"74","author":"Zacharia","year":"2014","journal-title":"Neurosurgery"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib58","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1007\/s12022-020-09647-w","article-title":"Effects of CAPTEM (capecitabine and temozolomide) on a corticotroph carcinoma and an aggressive corticotroph tumor","volume":"32","author":"Nakano-Tateno","year":"2021","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.beem.2022.101713_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.731631","article-title":"Aggressive pituitary macroadenoma treated with capecitabine and temozolomide chemotherapy combination in a patient with nelson's syndrome: a case report","volume":"12","author":"Mirallas","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.beem.2022.101713_bib60","article-title":"Chemotherapy of capecitabine plus temozolomide for refractory pituitary adenoma after tumor resection and its impact on serum prolactin, IGF-1, and growth hormone","volume":"2022","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"issue":"11","key":"10.1016\/j.beem.2022.101713_bib61","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1001\/jamaoncol.2017.1269","article-title":"Predictors of hand-foot syndrome and pyridoxine for prevention of capecitabine-induced hand-foot syndrome: a randomized clinical trial","volume":"3","author":"Yap","year":"2017","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib62","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1055\/a-1260-3975","article-title":"Bevacizumab in aggressive pituitary adenomas - experience with 3 patients","volume":"129","author":"Osterhage","year":"2021","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"10.1016\/j.beem.2022.101713_bib63","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jocn.2017.02.052","article-title":"Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection","volume":"41","author":"Touma","year":"2017","journal-title":"J\u00a0Clin Neurosci"},{"issue":"8","key":"10.1016\/j.beem.2022.101713_bib64","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1210\/jc.2019-00432","article-title":"Surgery, octreotide, temozolomide, bevacizumab, radiotherapy, and pegvisomant treatment of an AIP MutationPositive child","volume":"104","author":"Dutta","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.beem.2022.101713_bib65","first-page":"S1878","article-title":"Apatinib (YN968D1) and temozolomide in recurrent invasive pituitary adenoma: case report and literature review","volume":"10","author":"Wang","year":"2019","journal-title":"World Neurosurg"},{"issue":"1","key":"10.1016\/j.beem.2022.101713_bib66","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s11060-014-1702-0","article-title":"Temozolomide and pasireotide treatment for aggressive pituitary adenoma: expertise at a tertiary care center","volume":"122","author":"Ceccato","year":"2015","journal-title":"J\u00a0Neuro Oncol"},{"issue":"5","key":"10.1016\/j.beem.2022.101713_bib67","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3174\/ajnr.A5127","article-title":"Classification of high-grade glioma into tumor and nontumor components using support vector machine","volume":"38","author":"Blumenthal","year":"2017","journal-title":"AJNR Am J Neuroradiol"},{"issue":"10","key":"10.1016\/j.beem.2022.101713_bib68","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1093\/neuonc\/not036","article-title":"Secondary hematological malignancies associated with temozolomide in patients with glioma","volume":"15","author":"Momota","year":"2013","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib69","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1210\/jc.2016-3402","article-title":"Radiotherapy, especially at young age, increases the risk for de novo brain tumors in patients treated for pituitary\/sellar lesions","volume":"102","author":"Burman","year":"2017","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.beem.2022.101713_bib70","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S2213-8587(22)00160-7","article-title":"Risk of second brain tumour after radiotherapy for pituitary adenoma or craniopharyngioma: a retrospective, multicentre, cohort study of 3679 patients with long-term imaging surveillance","volume":"10","author":"Hamblin","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1093\/neuonc\/nop030","article-title":"Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma","volume":"12","author":"Kong","year":"2010","journal-title":"Neuro Oncol"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib72","article-title":"Immunotherapy in corticotroph and lactotroph aggressive tumors and carcinomas: two case reports and a review of the literature","volume":"10","author":"Duhamel","year":"2020","journal-title":"J\u00a0Personalized Med"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib73","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF02738884","article-title":"Vascular endothelial growth factor (VEGF) expression in human pituitary adenomas and carcinomas","volume":"10","author":"Lloyd","year":"1999","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.beem.2022.101713_bib74","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1158\/1078-0432.CCR-07-1552","article-title":"Blocking vascular endothelial growth factor-A inhibits the growth of pituitary adenomas and lowers serum prolactin level in a mouse model of multiple endocrine neoplasia type 1","volume":"14","author":"Korsisaari","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.beem.2022.101713_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020308","article-title":"Exploring the role of novel medical therapies for aggressive pituitary tumors: a review of the Literature-\"Are we there yet?\"","volume":"12","author":"Lamb","year":"2020","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.beem.2022.101713_bib76","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/cr.2015.20","article-title":"Recurrent gain-of-function USP8 mutations in Cushing's disease","volume":"25","author":"Ma","year":"2015","journal-title":"Cell Res"},{"issue":"1","key":"10.1016\/j.beem.2022.101713_bib77","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1210\/me.2010-0353","article-title":"HER2\/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy","volume":"25","author":"Fukuoka","year":"2011","journal-title":"Mol Endocrinol"},{"issue":"6","key":"10.1016\/j.beem.2022.101713_bib78","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1210\/jc.2018-02461","article-title":"Effect of everolimus in treatment of aggressive prolactin-secreting pituitary adenomas","volume":"104","author":"Zhang","year":"2019","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.beem.2022.101713_bib79","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2217\/cns-2016-0011","article-title":"Widely metastatic atypical pituitary adenoma with mTOR pathway STK11(F298L) mutation treated with everolimus therapy","volume":"5","author":"Donovan","year":"2016","journal-title":"CNS Oncol"},{"issue":"5","key":"10.1016\/j.beem.2022.101713_bib80","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1530\/EC-19-0065","article-title":"Peptide receptor radionuclide therapy for aggressive pituitary tumors: a monocentric experience","volume":"8","author":"Giuffrida","year":"2019","journal-title":"Endocr Connect"},{"issue":"6","key":"10.1016\/j.beem.2022.101713_bib81","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.3171\/2018.2.FOCUS17660","article-title":"Regression of a nonfunctioning pituitary macroadenoma on the CDK4\/6 inhibitor palbociclib: case report","volume":"44","author":"Anderson","year":"2018","journal-title":"Neurosurg Focus"},{"issue":"5","key":"10.1016\/j.beem.2022.101713_bib82","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1210\/jc.2004-2231","article-title":"Clinical review: diagnosis and management of pituitary carcinomas","volume":"90","author":"Kaltsas","year":"2005","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.beem.2022.101713_bib83","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s12020-019-01996-9","article-title":"Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide","volume":"65","author":"Aharon-Hananel","year":"2019","journal-title":"Endocrine"}],"container-title":["Best Practice &amp; Research Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22001002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X22001002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:58:47Z","timestamp":1761497927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X22001002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":83,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S1521690X22001002"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2022.101713","relation":{},"ISSN":["1521-690X"],"issn-type":[{"value":"1521-690X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Temozolomide in aggressive pituitary tumours and pituitary carcinomas","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2022.101713","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101713"}}